BioCeramic Therapeutics, a biomaterials company, and its principal founder and chief scientific officer, Molly Stevens of Imperial College London, have won the prestigious ACES Academic Enterprise Award (in the Life Sciences category), in Paris, France. The award, sponsored by Amgen International, recognized the company's potential and achievements in rapidly bringing the work of Professor Stevens and her colleagues from the laboratory bench to the point of commercialization. BioCeramic Therapeutics was founded in 2006 by Professors Molly Stevens and Robert Hill, and CEO Daniel Green. BioCeramic Therapeutics’ products are designed to benefit patients with serious orthopedic and dental conditions by stimulating and assisting in the body's natural tissue regeneration processes. The materials innovations also have potential future applications in soft tissue regeneration. The European Awards for University Entrepreneurs aim to give public recognition to those who have done the most in 2009 to foster a culture of enterprise, the ultimate aim being to improve the flow of ideas out of European laboratories and into the marketplace. The prizes were awarded by the Science-Business Innovation Board.